dr. horn on the role of mobocertinib in nsclc
Published 4 years ago • 211 plays • Length 1:07Download video MP4
Download video MP3
Similar videos
-
1:08
dr. horn on the fda approval of atezolizumab plus bevacizumab and chemotherapy in nsclc
-
1:37
dr. horn on incorporating t790m-mutant nsclc agents into nccn guidelines
-
2:03
nsclc with egfr exon 20 shows benefit with mobocertinib over chemotherapy
-
1:32
real-world comparison assesses mobocertinib in nsclc with egfr exon 20
-
1:22
dr. horn on updated data from impower133 in small cell lung cancer
-
0:51
dr. leora horn on toxicities with immunotherapy in lung cancer
-
6:17
asco 2021 lung recap: amivantamab and mobocertinib for egfr exon 20
-
2:06
dr. rintoul on the importance of mrd assessment in nsclc
-
4:47
treating non–small cell lung cancer with an egfr exon 20 insertion
-
6:07
amivantamab and mobocertinib for egfr exon-20 disease - lung cancer video library
-
1:14
evaluating the role of egfr mutations in the treatment of advanced nsclc
-
1:42
mobocertinib for previously treated nsclc with efgr mutations
-
1:41
dr. heymach on the significance of nivolumab for lung cancer
-
1:33
dr. chaft on the rise of immunotherapy in lung cancer
-
1:26
dr. oxnard on the role of osimertinib in the tatton trial for lung cancer
-
1:05
efficacy of mobocertinib in patients previously treated with tkis
-
1:37
dr. konduri on treatment options for patients with egfr-mutant nsclc
-
4:45
amivantamab and mobocertinib: side effects and treatment timing - lung cancer
-
1:53
dr. mok on the utility of afatinib in lung cancer